<DOC>
	<DOCNO>NCT00327678</DOCNO>
	<brief_summary>This study multicenter trial treatment young ALL patient . All ALL patient receive steroid pre-phase order evaluate sensitivity resistance . Then , patient include 3 specific trial accord biological feature ( immunophenotype , cytogenetics , molecular biology ) . Group Research Adult Acute Lymphoblastic Leukemia ( GRAALL ) 2005 : - T ALL B ALL non Ph ( N=810 patient plan ) . - GRAALL 2005 R : B ALL non Ph CD20+ ( N=220 patient plan ) . - GRAAPH 2005 : ALL Ph+ ( N=270 patient plan )</brief_summary>
	<brief_title>Treatment Acute Lymphoblastic Leukemia ( ALL ) Younger Adults</brief_title>
	<detailed_description>GRAALL 2005 : T ALL B ALL non Ph Randomization standard versus intensify cyclophosphamide administration 4-drug , 4 week chemotherapy late intensification . ( N=810 patient plan ) GRAALL 2005 R : B ALL non Ph CD20+ Randomization standard versus intensify cyclophosphamide administration 4-drug , 4 week chemotherapy late intensification . Randomization Mabthera ( rituximab ) Mabthera induction consolidation course . ( N=220 patient plan ) Allogenic transplantation perform depend unfavourable risk factor . GRAAPH 2005 : ALL Ph Randomization imatinib-based induction chemotherapy + imatinib induction . ( N=270 patient plan ) Allogenic transplantation systematically perform presence relate unrelated donor . Autologous transplantation could perform absence donor case Molecular Residual Disease ( MRD ) â‰¤ 10-4 . Consolidation therapy perform absence donor case MRD &gt; 10-4 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1859 year ALL newly diagnose ( blast &lt; 20 % ) Central Nervous System ( CNS ) positive negative Signed write informed consent For GRAAPH trial : ( 9 ; 22 ) BCR ABL positive Lymphoblastic lymphoma ALL 3 Chronic myeloid leukemia Severe organ condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ALL ,</keyword>
	<keyword>young patient ,</keyword>
	<keyword>chemotherapy ,</keyword>
	<keyword>Mabtera ,</keyword>
	<keyword>Imatinib ,</keyword>
	<keyword>allogeneic transplant</keyword>
</DOC>